

Strategy Overview

The Cambria Cannabis ETF (TOKE): seeks capital appreciation from investments in the global equity markets that have exposure to the broad cannabis industry. The strategy targets companies across a range of market capitalizations that derive a significant portion of revenue from the legal sale, cultivation, production, or provision of cannabis-related products, services, or research.

Fund Description

The Cambria Cannabis ETF targets investing in approximately 20 to 50 companies with exposure to the broad cannabis industry based on Cambria's proprietary quantitative metrics and its determination as to their exposure to the industry. The fund is offered at a net expense ratio 0.42% for cost-conscious investors looking for a broad allocation to the cannabis industry.

Fund Details

Fund Inception	7/25/2019
Ticker Symbol	TOKE
Listing Exchange	CBOE BZX formerly known as BATS
CUSIP	132061821
Fund Type	Active ETF
Investment Objective	Capital Appreciation
Gross Expense Ratio	0.59%
Net Expense Ratio*	0.42%
Indicative Value	TOKE.IV
Net Asset Value (NAV)	TOKE.NV
Number of Holdings	30
Dividend Frequency	Quarterly

*Fee waivers are contractual and in effect until August 31, 2020.

Total Returns

as of July 25, 2019

	1 Month	3 Months	6 Months	1 Year	Annualized Since Inception	Cumulative Since Inception
Cambria Cannabis ETF NAV	-	-	-	-	-	-
Cambria Cannabis ETF Market Price	-	-	-	-	-	-

Returns for periods greater than one year are annualized. The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. Market price returns are based upon the midpoint of the bid/ask spread at 4:00 Eastern Time and do not represent the returns you would receive if you traded shares at other times. For performance data current to the most recent month end, please call 855-383-4636 (ETF INFO) or visit www.cambriafunds.com.

Top 10 Holdings

as of July 25, 2019



• Aurora Cannabis Inc	7%
• Aphria Inc	5%
• Canopy Growth Corp	5%
• GW Pharmaceuticals - ADR	5%
• Greenlane Holdings Inc - A	5%
• MediPharm Labs Corp	5%
• Constellation Brands	5%
• OrganiGram Holdings Inc	4%
• Tilray Inc - Class 2	4%
• Canopy Rivers Inc	4%

Holdings and allocations are subject to risks and to change.

Cambria Investment Management, LP, based in Los Angeles, California, is a SEC registered investment management firm employing a disciplined multi-asset, global quantitative research process. Cambria provides investment management services through a number of portfolio strategies to high net worth individuals and institutions through exchange traded funds, separately managed accounts and private funds. Cambria is also the investment manager of the Cambria Shareholder Yield ETF (BATS: SYLD), Cambria Global Value ETF (BATS: GVAL), the Cambria Foreign Shareholder Yield ETF (BATS: FYLD), the Cambria Global Momentum ETF (BATS: GMOM), the Cambria Value and Momentum ETF (BATS: VAMO), the Cambria Sovereign High Yield Bond ETF (BATS: SOVB), the Cambria Emerging Shareholder Yield ETF (BATS: EYLD), the Cambria Tail Risk ETF (BATS: TAIL), the Cambria Core Equity ETF (NYSE: CCOR), the Cambria Trinity ETF (BATS: TRTY), and the Cambria Cannabis ETF (BATS: TOKE). Cambria believes that any single style or approach that relies on subjective methods can be inconsistent over time, may bias the investment process, and potentially hinder performance. Global diversification through asset allocation, coupled with prudent risk management, is the foundation of Cambria's investment philosophy.



Cambria Investment Management, LP

2321 Rosecrans Avenue, Suite 3225
El Segundo, CA 90245
(310) 683-5500
www.cambriafunds.com

To determine if this Fund is an appropriate investment for you, carefully consider the Fund's investment objectives, risk factors, charges and expense before investing. This and other information can be found in the Fund's full and summary prospectus which may be obtained by calling 855-383-4636 (ETF INFO) or visiting our website at www.cambriafunds.com. Read the prospectus carefully before investing or sending money.

The Cambria ETFs are distributed by SEI Investments Distribution Company, 1 Freedom Valley Drive, Oaks, PA 19456, which is not affiliated with Cambria Investment Management, LP, the Investment Adviser for the Fund.

ETFs are subject to commission costs each time a "buy" or "sell" is executed. Depending on the amount of trading activity, the low costs of ETFs may be outweighed by commissions and related trading costs.

Shares are bought and sold at market price (closing price) not net asset value (NAV) are not individually redeemed from the Fund. Market price returns are based on the midpoint of the bid/ask spread at 4:00 pm Eastern Time (when NAV is normally determined), and do not represent the return you would receive if you traded at other times. Buying and selling shares will result in brokerage commissions. Brokerage commissions will reduce returns.

Investing involves risk, including the possible loss of principal. In addition to the normal risks associated with investing, international investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from social, economic, or political instability in other nations. These risks are especially high in emerging markets.

Cannabis Companies are subject to various laws and regulations that may differ at the local and federal level. They are subject to the risks associated with the agricultural, biotechnology, and pharmaceutical industries. Since the use of marijuana is illegal under United States federal law, federally regulated banking institutions may be unwilling to make financial services available to growers and sellers of marijuana. The Fund's investments are concentrated in the cannabis industry, and the Fund may be susceptible to loss due to adverse occurrences affecting this industry. The Fund is also expected to have significant exposure to the health care, consumer discretionary, and consumer staples sectors.

The fund is actively managed using proprietary investment strategies and processes. There can be no guarantee that these strategies and processes will produce the intended results and no guarantee that the Fund will achieve its investment objective. This could result in the Fund's underperformance compared to other funds with similar investment objectives.